Ocumension Therapeutics Management
Management criteria checks 2/4
Ocumension Therapeutics' CEO is Victor Liu, appointed in Aug 2018, has a tenure of 6.33 years. total yearly compensation is CN¥5.94M, comprised of 71.5% salary and 28.5% bonuses, including company stock and options. directly owns 4.15% of the company’s shares, worth HK$149.51M. The average tenure of the management team and the board of directors is 3.9 years and 5.1 years respectively.
Key information
Victor Liu
Chief executive officer
CN¥5.9m
Total compensation
| CEO salary percentage | 71.5% |
| CEO tenure | 6.3yrs |
| CEO ownership | 4.2% |
| Management average tenure | 3.9yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For
Sep 21
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results
Aug 15We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now
Jun 13Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable
Apr 29Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation
Mar 14Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates
Aug 29We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely
Jul 13Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?
Jun 02We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Jan 20We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Sep 27Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?
Jan 23
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥323m |
| Mar 31 2024 | n/a | n/a | -CN¥351m |
| Dec 31 2023 | CN¥6m | CN¥4m | -CN¥380m |
| Sep 30 2023 | n/a | n/a | -CN¥399m |
| Jun 30 2023 | n/a | n/a | -CN¥418m |
| Mar 31 2023 | n/a | n/a | -CN¥411m |
| Dec 31 2022 | CN¥5m | CN¥3m | -CN¥403m |
| Sep 30 2022 | n/a | n/a | -CN¥393m |
| Jun 30 2022 | n/a | n/a | -CN¥383m |
| Mar 31 2022 | n/a | n/a | -CN¥322m |
| Dec 31 2021 | CN¥5m | CN¥4m | -CN¥260m |
Compensation vs Market: Victor's total compensation ($USD814.29K) is above average for companies of similar size in the Hong Kong market ($USD392.71K).
Compensation vs Earnings: Victor's compensation has increased whilst the company is unprofitable.
CEO
Victor Liu (53 yo)
6.3yrs
Tenure
CN¥5,943,000
Compensation
Mr. Ye Liu, also known as Victor, serves as Chief Executive Officer at Ocumension Therapeutics since joining on August 1, 2018 and has been its Executive Director since November 23, 2018. Mr. Liu is respon...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 6.3yrs | CN¥5.94m | 4.15% HK$ 149.5m | |
| Chief Development Officer & Executive Director | 4.5yrs | CN¥2.21m | 0.46% HK$ 16.5m | |
| CFO & Joint Company Secretary | 1.9yrs | no data | no data | |
| Chief Medical Officer | 5.2yrs | no data | no data | |
| Chief Commercial Officer | 3.9yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Joint Company Secretary | 1.3yrs | no data | no data |
3.9yrs
Average Tenure
45.5yo
Average Age
Experienced Management: 1477's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 6.1yrs | CN¥5.94m | 4.15% HK$ 149.5m | |
| Chief Development Officer & Executive Director | 4.7yrs | CN¥2.21m | 0.46% HK$ 16.5m | |
| Non-Executive Director | 5.5yrs | no data | no data | |
| Independent Non-Executive Director | 4.5yrs | CN¥720.00k | no data | |
| Non-Executive Chairman of the Board | 6.6yrs | no data | 15.45% HK$ 556.5m | |
| Independent Non-Executive Director | 2.7yrs | CN¥135.00k | no data | |
| Independent Non-Executive Director | 4.5yrs | CN¥180.00k | no data | |
| Non-Executive Director | 6.7yrs | no data | no data |
5.1yrs
Average Tenure
52.5yo
Average Age
Experienced Board: 1477's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 22:04 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ocumension Therapeutics is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Fang Quan | China International Capital Corporation Limited |
| Ziyi Chen | Goldman Sachs |